| Literature DB >> 30820840 |
Antonio Lalueza1,2,3, Dolores Folgueira4,5,6, Irene Muñoz-Gallego6, Hernando Trujillo7, Jaime Laureiro7, Pilar Hernández-Jiménez7, Noelia Moral-Jiménez6, Cristina Castillo7, Blanca Ayuso7, Carmen Díaz-Pedroche7,4, Marta Torres7, Estibaliz Arrieta7, Coral Arévalo-Cañas7, Olaya Madrid7, Carlos Lumbreras7,4,5,8.
Abstract
The role of viral load in the outcome of patients requiring hospital admission due to influenza is not well established. We aim to assess if there is an association between the viral load and the outcome in hospitalized patients with a confirmed influenza virus infection. A retrospective observational study including all adult patients who were hospitalized in our center with a confirmed influenza virus infection from January to May 2016. Viral load was measured by real-time reverse-transcriptase-polymerase chain reaction (rRT-PCR) cycle threshold (Ct) value on upper respiratory tract samples. Its value was categorized into three groups (low Ct, ≤ 20; intermediate Ct, > 20-30; and high Ct, > 30). Two hundred thirty-nine patients were included. Influenza A/H1N1pdm09 was isolated in 207 cases (86.6%). The mean Ct value was 26.69 ± 5.81. The viral load was higher in the unvaccinated group when compared with the vaccinated patients (Ct 25.17 ± 5.55 vs. 27.58 ± 4.97, p = 0.004). Only 27 patients (11.29%) presented a high viral load. Patients with a high viral load more often showed abnormal findings on chest X-ray (p = 0.015) and lymphopenia (p = 0.097). By contrast, there were no differences between the three groups (according to viral load), in associated pneumonia, respiratory failure, need for mechanical ventilation, sepsis, or in-hospital mortality. Our findings suggest that in patients admitted to the hospital with confirmed influenza virus infection (mostly A/H1N1pdm09), a high viral load is associated with a higher presence of abnormal findings on chest X-ray but not with a significant worse prognosis. In these cases, standardized quantitative PCR could be useful.Entities:
Keywords: Influenza; Lymphopenia; Mortality; Outcome; Pneumonia; Viral load
Mesh:
Year: 2019 PMID: 30820840 PMCID: PMC7102091 DOI: 10.1007/s10096-019-03514-1
Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN: 0934-9723 Impact factor: 3.267
Baseline demographic and clinical characteristics of patients with influenza infection
| Characteristics | All patients ( | Ct value (viral load) | ||||
|---|---|---|---|---|---|---|
| ≤ 20 ( | > 20–30 ( | > 30 ( | ||||
| Age (years) | 67.08 ± 16.09 | 70.11 ± 15.91 | 66.13 ± 16.56 | 67.72 ± 15.29 | 0.46 | 0.21 |
| Sex (male) | 142 (59.7%) | 18 (66.7%) | 78 (56.9%) | 46 (62.2%) | 0.55 | 0.41 |
| Charlson comorbidity index score | 2 (1–4) | 2 (0.25–3.75) | 2 (1–4) | 2 (1–3) | 0.58 | 0.33 |
| Previous comorbid conditions | ||||||
| Active smoker | 48 (20.1%) | 5 (18.5%) | 29 (21%) | 14 (18.9%) | 0.91 | 0.82 |
| Obesity | 43 (18%) | 6 (22.2%) | 24 (17.4%) | 13 (17.6%) | 0.83 | 0.59 |
| Asthma | 15 (6.3%) | 1 (3.7%) | 10 (7.2%) | 4 (5.4%) | 0.73 | 1 |
| COPD | 51 (21.3%) | 5 (18.5%) | 33 (23.9%) | 13 (17.6%) | 0.52 | 0.7 |
| Cardiovascular disease | 68 (28.5%) | 6 (22.2%) | 38 (27.5%) | 24 (32.4%) | 0.56 | 0.44 |
| Immunosuppression (including steroids)* | 53 (22.2%) | 3 (11.1%) | 34 (24.6%) | 16 (21.6%) | 0.29 | 0.14 |
| Influenza vaccination (last year) | 96 (40.3%) | 10 (37%) | 50 (36.5%) | 36 (48.6%) | 0.21 | 0.71 |
| Influenza A H1N1pdm09 (vs influenza B) | 207 (86.6%) | 27 (100%) | 125 (90.6%) | 55 (74.3%) |
|
|
| Duration of illness prior to confirming the infection (days) | 3 (2–5) | 3 (1–7) | 3 (2–4.75) | 3.5 (2–5) | 0.114 | 0.54 |
| Clinical findings at admission | ||||||
| Temperature (°C) | 37.62 ± 1.02 | 37.9 ± 0.9 | 37.58 ± 0.99 | 37.60 ± 1.11 | 0.39 | 0.17 |
| Dyspnea | 142 (59.4%) | 18 (66.7%) | 88 (63.8%) | 36 (48.6%) | 0.073 | 0.41 |
| Respiratory rate | 19.95 ± 7.97 | 23.83 ± 11.66 | 19.38 ± 7.41 | 20.26 ± 8.29 | 0.71 | 0.45 |
| SpO2 (%) | 91.28 ± 5.95 | 90.92 ± 4.72 | 91.47 ± 5.1 | 91.04 ± 5.13 | 0.59 | 0.52 |
| Bronchospasm | 102 (42.7%) | 9 (33.3%) | 54 (39.1%) | 39 (52.7%) | 0.095 | 0.29 |
| Chest X-ray abnormal findings | 113 (50.2%) | 20 (76.9%) | 61 (46.9%) | 32 (46.4%) |
|
|
| Treatment | ||||||
| Oseltamivir | 231 (96.7%) | 27 (100%) | 134 (97.1%) | 70 (94.6%) | 0.37 | 0.6 |
| Empiric antibiotic therapy | 174 (72.8%) | 17 (63%) | 103 (74.6%) | 54 (73%) | 0.45 | 0.22 |
| Pathogen directed antibiotic therapy | 17 (7.1%) | 3 (11.1%) | 9 (6.5%) | 5 (6.8%) | 0.69 | 0.41 |
| Treatment with steroids | 136 (56.9%) | 17 (63%) | 76 (55.1%) | 43 (58.1%) | 0.72 | 0.32 |
Results are expressed as mean ± standard deviation or median with interquartile range (IQR) or as absolute value (percentage). *Immunosuppression was defined as the presence of any the following: active malignant neoplasia, autoimmune disease, solid organ transplantation, HIV infection, use of steroids or chemotherapy. Use of steroids was defined as (1) more than 20 mg/day of oral prednisone during 7 days or longer or (2) less than 20 mg/day during a minimum of 3 months. COPD chronic obstructive pulmonary disease. aAcross all Ct value groups. bBetween high viral load group (Ct ≤ 20) and other groups combined. Bold font means significant differences between variables
Laboratory parameters of patients with influenza infection
| Characteristics | All patients ( | Ct value (viral load) | ||||
|---|---|---|---|---|---|---|
| ≤ 20 ( | > 20–30 ( | > 30 ( | ||||
| Baseline laboratory findings | ||||||
| Leukocytes (×103 cells/μl) | 8.1 (5.55–10.95) | 8.2 (5.55–11.2) | 8.1 (5.55–10.9) | 8.2 (5.55–11.2) | 0.86 | 0.63 |
| Neutrophils (×103 cells/μl) | 6.1 (3.85–9.15) | 6.2 (3.3–9.8) | 6 (3.7–9.15) | 6.3 (4.15–9) | 0.93 | 0.79 |
| Neutrophils (%) | 76.71 ± 13.69 | 82.61 ± 9.9 | 75.82 ± 13.24 | 76.42 ± 15.6 |
|
|
| Lymphocytes (cells/μl) | 800 (500–1200) | 500 (400–800) | 900 (600–1300) | 700 (450–1200) |
|
|
| Lymphocytes (%) | 11 (6.02–18) | 7.8 (4.3–16) | 11.8 (6.32–20.45) | 11 (5.5–16.8) | 0.11 | 0.071 |
| Platelets (×103/μl) | 187 (146–245) | 159 (118–269) | 204 (155–246.5) | 183 (133–231) | 0.28 | 0.48 |
| Hemoglobin (g/dl) | 13.06 ± 2.13 | 13.41 ± 1.41 | 12.92 ± 2.33 | 13.22 ± 2.02 | 0.51 | 0.52 |
| LDH (U/l) | 274.5 (223.7–347.7) | 324 (223.7–392) | 278 (227–364) | 261 (221–319) | 0.15 | 0.23 |
| Hypertransaminasemia | 48 (20.1%) | 7 (25.9%) | 35 (25.4%) | 6 (8.1%) |
| 0.42 |
| C-reactive protein (mg/dl) | 5.31 (2.44–11.55) | 7.49 (3.72–11.87) | 5.36 (2.45–11.94) | 4.61 (2.13–9.95) | 0.25 | 0.15 |
| Peak laboratory values | ||||||
| LDH (U/l) | 292 (247.5–394.5) | 329 (248–537) | 296 (253–386) | 276 (240–366) | 0.25 | 0.15 |
| LDH > 225¶ | 196 (83.8%) | 22 (81.5%) | 114 (85.1%) | 60 (82.2%) | 0.81 | 0.78 |
| AST (mg/dl) | 30 (23–51) | 51 (22–79) | 30 (23.75–44.2) | 27 (22–44) | 0.29 | 0.064 |
| C-reactive protein (mg/dl) | 8 (4–15) | 10 (4.75–13.5) | 8 (4–15.5) | 8 (3–15) | 0.77 | 0.34 |
| Nadir blood cell count | ||||||
| Leukocytes (×103 cells/μl) | 5.8 (4.15–8.1) | 5.7 (3.9–8.5) | 5.8 (4.12–7.7) | 6.35 (4.27–8.45) | 0.73 | 0.9 |
| Neutrophils (×103 cells/μl) | 3.7 (2.4–5.65) | 3.9 (2.2–6.2) | 3.4 (2.4–5.27) | 4.45 (2.8–6.32) | 0.61 | 0.8 |
| Neutrophils (%) | 64.09 ± 16.39 | 68.5 ± 15.23 | 62.14 ± 16.47 | 66.07 ± 16.29 | 0.13 | 0.14 |
| Lymphocytes (cells/μl) | 700 (400–1000) | 500 (300–700) | 700 (500–1000) | 600 (400–1100) | 0.09 |
|
| Lymphocytes (%) | 9.4 (5.1–16.5) | 7.15 (4.07–16) | 10.2 (5.6–16.3) | 9.2 (4.75–16.8) | 0.27 | 0.13 |
| Platelets (×103/μl) | 176 (119–227.5) | 134 (99–235) | 178 (135.5–228) | 172 (109–221.2) | 0.3 | 0.24 |
| Hemoglobin (g/dl) | 11.96 ± 2.35 | 11.89 ± 2.06 | 11.92 ± 2.54 | 12.08 ± 2.11 | 0.94 | 0.85 |
| Hematological abnormalities | ||||||
| < 1000 neutrophils/μl* | 14 (5.9%) | 2 (7.4%) | 7 (5.1%) | 5 (6.8%) | 0.82 | 0.66 |
| < 100,000 platelets/μl* | 36 (15.1%) | 7 (25.9%) | 16 (11.6%) | 13 (17.6%) | 0.12 | 0.14 |
| Hemoglobin < 9 g/dl* | 25 (10.5%) | 3 (11.1%) | 17 (12.3%) | 5 (6.8%) | 0.45 | 1 |
| < 1000 lymphocytes/μl | 170 (71.7%) | 24 (88.9%) | 93 (68.4%) | 53 (71.6%) | 0.097 |
|
Results are expressed as mean ± standard deviation or median with interquartile range (IQR) or as absolute value (percentage). NA not available. ¶Upper limit of LDH in the local laboratory is 225 mg/dl. *According to the HLH-04 criteria. aAcross all Ct value groups. bBetween high viral load group (Ct ≤ 20) and other groups combined. Bold font means significant differences between variables
Outcome of patients with influenza infection according viral load
| Characteristics | All patients ( | Ct value (viral load) | ||||
|---|---|---|---|---|---|---|
| ≤ 20 ( | > 20–30 ( | > 30 ( | ||||
| Length of hospital stay (days) | 7 (5–12) | 9 (6–13) | 7 (5–11) | 8 (5–12.25) | 0.19 | 0.34 |
| ICU admission | 13 (5.4%) | 2 (7.4%) | 5 (3.6%) | 6 (8.1%) | 0.34 | 0.64 |
| Pneumonia | 28 (11.7%) | 5 (18.5%) | 16 (11.6%) | 7 (9.5%) | 0.45 | 0.33 |
| Respiratory failure | 19 (7.9%) | 3 (11.1%) | 9 (6.5%) | 7 (9.5%) | 0.61 | 0.45 |
| ARDS | 3 (1.3%) | 0 (0%) | 1 (0.7%) | 2 (2.7%) | 0.38 | 1 |
| Invasive mechanical ventilation | 9 (3.8%) | 2 (7.4%) | 2 (1.4%) | 5 (6.8%) | 0.08 | 0.27 |
| Non-invasive mechanical ventilation | 8 (3.3%) | 1 (3.7%) | 4 (2.9%) | 3 (4.1%) | 0.9 | 1 |
| Duration of invasive mechanical ventilation (days) | 15.5 (8–28.5) | 22.5 (15–30) | 8 (4–18) | 16 (10–19) | 0.43 | 0.4 |
| Vasoactive drugs | 10 (4.2%) | 2 (7.4%) | 4 (2.9%) | 4 (5.4%) | 0.46 | 0.31 |
| Septic shock | 13 (5.4%) | 3 (11.1%) | 4 (2.9%) | 6 (8.1%) | 0.10 | 0.17 |
| SOFA score at ICU admission | 1 (0–3.75) | 3 (1.5–7.5) | 0 (0–3) | 2 (0.5–3.5) | 0.44 | 0.49 |
| SOFA ≥ 2 | 30 (15.1%) | 4 (19%) | 18 (15.7%) | 8 (12.7%) | 0.75 | 0.53 |
| qSOFA score | 0 (0–1) | 0 (0–1) | 0 (0–1) | 0 (0–1) | 0.19 | 0.98 |
| qSOFA ≥ 1 | 58 (39.5%) | 5 (35.7%) | 29 (34.9%) | 24 (48%) | 0.31 | 0.76 |
| Overall in-hospital mortality | 12 (5.2%) | 2 (7.7%) | 6 (4.5%) | 4 (5.5%) | 0.79 | 0.63 |
| Related mortality | 10 (4.3%) | 2 (7.7%) | 5 (3.8%) | 3 (4.1%) | 0.66 | 0.31 |
| Poor outcome (composite endpoint) | 42 (21.4%) | 5 (25%) | 26 (22.8%) | 11 (17.7%) | 0.67 | 0.77 |
Results are expressed as mean ± standard deviation or median with interquartile range (IQR) or as absolute value (percentage). ICU intensive care unit, ARDS acute respiratory distress syndrome. aAcross all Ct value groups. bBetween high viral load group (Ct ≤ 20) and other groups combined
Fig. 1Respiratory failure and poor outcome according to Ct value. a Receiver operator characteristic (ROC) curve analysis using the value of Ct for discriminating respiratory failure (AUC = 0.53; 0.38–0.69, p = 0.59). b ROC curve analysis using the value of Ct for discriminating poor outcome (defined as a composite endpoint in which at least one of the following criteria had to be fulfilled: (a) respiratory failure, (b) SOFA ≥ 2, or (c) death (related or not related to influenza infection) (AUC = 0.51; 0.41–0.61, p = 0.82)
Length of hospitalization (in days) according influenza viral load
| Characteristics | All patients ( | Ct value (viral load) | ||||
|---|---|---|---|---|---|---|
| ≤ 20 ( | > 20–30 ( | > 30 ( | ||||
| All cases | 7 (5–12) | 9 (6–13) | 7 (5–11) | 8 (5–12.25) | 0.19 | 0.34 |
| Pneumonia | 9 (5.25–14.75) | 13 (9–38.5) | 8 (4–10.75) | 9 (6–26) | 0.12 | 0.098 |
| Respiratory failure | 15.5 (8.5–51.5) | 45 (15-NA) | 13 (7–39.5) | 26 (14–53) | 0.447 | 0.26 |
| Poor outcome | 13 (6.75–33.25) | 37 (12.5–53.5) | 8 (5–17.5) | 14 (11–32) | 0.223 | 0.091 |
Results are expressed as median with interquartile range (IQR). aAcross all Ct value groups. bBetween high viral load group (Ct ≤ 20) and other groups combined